Emerald Health Therapeutics (CVE:EMH) has been assigned a C$4.30 target price by analysts at Jefferies Financial Group in a report issued on Monday, February 25th. The firm presently has a “hold” rating on the stock. Jefferies Financial Group’s price target points to a potential upside of 2.38% from the company’s previous close.
Shares of EMH traded down C$0.25 during mid-day trading on Monday, hitting C$4.20. The company’s stock had a trading volume of 946,700 shares, compared to its average volume of 1,005,065. Emerald Health Therapeutics has a 52-week low of C$2.04 and a 52-week high of C$5.92. The stock has a market capitalization of $626.78 million and a PE ratio of -24.42. The company has a debt-to-equity ratio of 1.48, a quick ratio of 2.03 and a current ratio of 2.29.
About Emerald Health Therapeutics
Emerald Health Therapeutics, Inc, together with its subsidiaries, produces and sells medical cannabis in Canada. The company was formerly known as T-Bird Pharma Inc and changed its name to Emerald Health Therapeutics, Inc in June 2015. Emerald Health Therapeutics, Inc is headquartered in Victoria, Canada.
Further Reading: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Emerald Health Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Health Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.